The pharmaceutical giant Bristol Myers Squibb (NYSE: BMY) has chosen Houston as the site for a new $2.3 billion manufacturing campus.
The new 600,000-square-foot campus will be modular and multi-modal. Its modular design will enable the company to add and reconfigure manufacturing capacity as needed, while its multi-modal capabilities will permit the manufacturing of multiple types of medicines across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch.
The campus will be based at Generation Park, a 4,300-acre curated hub for life sciences and advanced manufacturing. The company expects the campus to create approximately 2,000 construction and other indirect jobs between 2027–2030 as the facility is built and brought online, along with nearly 500 skilled jobs when the site is fully operational. The campus will be designed to accommodate growth in scale, capability and workforce.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said Christopher Boerner, board chairman and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”
0 Comments